EVALUATION OF THE EFFECTIVENESS OF THE ADDITIONAL RISK MINIMISATION MEASURES FOR GLOFITAMAB: A PASS SURVEY AMONG HEALTHCARE PROFESSIONALS IN EUROPEAN COUNTRIES

08/01/2026
12/01/2026
EU PAS number:
EUPAS1000000863
Study
Planned

ENCePP Code of conduct

Yes
Data sources

Data source(s), other

OneKeyTM database

Data sources (types)

Patient surveys
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No
Procedures
No information provided.